Outcomes

Effective

Neonatal:

Similar Efficacy to Nasal CPAP

Studies in post-extubation neonatal patients older than 26 weeks’ gestational age, have found that nasal high flow and nasal CPAP have similar efficacy^1,2,3.

Pediatric:

Associated with Reduced Escalation

Studies have found that the early use of Nasal High Flow therapy may reduce therapy escalation and decrease intubation rates^4,5,6,7.

Reduced PICU Admissions and Transfers

Evidence indicates that the early use of Nasal High Flow therapy may reduce PICU admissions⁴. This could also lead to a reduced need for inter-hospital transfers.

Positive PICU Outcomes

Evidence suggests that the introduction of Nasal High flow therapy in the PICU may be associated with fewer ventilation days and reduced PICU length of stay^5,8,9.

Gentle

Less Nasal Trauma

Randomized controlled trials have shown significantly lower rates of nasal trauma associated with Nasal High Flow therapy compared to nasal CPAP^1,2,3.

No Significant Difference in Adverse Events

Clinical studies have concluded that there appears to be no significant difference in other serious adverse events (i.e. pneumothorax) when compared to nasal CPAP^1,2,3.

Improved Mother-infant Bonding

Surveys of practice from around the world describe that parents are able to bond more easily with infants on Nasal High Flow therapy^10,11,12.

Comfortable and Well Tolerated

Research and surveys of practice have found that Optiflow™ Junior is comfortable and well-tolerated^{10,11, 12, 13}.

Easy

Simpler Application

Optiflow Junior has been designed to be easy to set-up. Surveys of practice describe easier application^4,6 and ongoing care with Nasal High Flow^10,11,12.

Empowers Parents

Parents have confidence to play a greater role in their infant’s care.

Parents reported a preference for NHF in a randomized cross-over trial involving 20 infants¹⁴. These findings are mirrored in surveys of practice^10,11,12.

Loved By Caregivers^10,11,12

Surveys of practice describe improved caregiver satisfaction.